Journal Article

Editorial: Translation and implementation of pharmacogenomic testing in daily clinical practice: Considering current challenges and future needs

Tafazoli, Alireza, Verstuyft, Celine, Patrinos, George P., Miltyk, Wojciech, Coenen, Marieke

2022

Overview

[...]available tools for functional characterization of changes in these genes could not be successful in strongly displaying the consequences of such alteration on drug pharmacokinetics (PK) and pharmacodynamics (PD) (Chang et al., 2021). Factors like lower background and expertise for clinical interpretation of PGx test result in physicians and clinicians, lack of particular cost and time benefit instruments and facilities for test implementation through clinical centers, absence of sufficient guidelines for every genomic variant in drug-related genes, no existence of appropriate variant calling tools for many pharmacogenes, no willing and hesitance of insurance parties to cover the tests in clinics, etc. are seen and introduced as the major issues for prevention of combination of PGx and primary care everywhere (Frick et al., 2016). The fourth and fifth articles (DPYD pre-clinical testing in Switzerland and mini review on genetic associations with severe adverse drug events) explored the prospect of prevention of adverse drug reactions (ADRs) through the utilization of clinical PGx tests and demonstrated the advantages of pre-emptive genotyping on anticipation of ADRs and acceleration of integration of PGx tests into daily primary care (Begré et al.;Wang et al.).

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: Clinical medicine / Conflicts of interest / daily clinical practice / Genes / PGx / Pharmacodynamics / pharmacogenetics / pharmacogenomic testing / Pharmacogenomics / Pharmacokinetics / Pharmacology / Primary care / public healthcare systems / Side effects